Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CureVac N-V is a biotechnology business based in the US. CureVac N-V stocks (CVAC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $98.2 – a decrease of 18.33% over the previous week. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around $48.9 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$55.11|
|52-week range||$43 - $151.8|
|50-day moving average||$63.2866|
|200-day moving average||$84.1018|
|Wall St. target price||$72.64|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.155|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-10)||-18.33%|
|1 month (2021-08-17)||-16.84%|
|3 months (2021-06-18)||-11.03%|
|6 months (2021-03-18)||-38.44%|
|1 year (2020-09-17)||4.18%|
|Revenue TTM||USD$48.9 million|
|Gross profit TTM||USD$34.7 million|
|Return on assets TTM||-10.17%|
|Return on equity TTM||-38.63%|
|Market capitalisation||USD$12.6 billion|
TTM: trailing 12 months
There are currently 4.5 million CureVac N-V stocks held short by investors – that's known as CureVac N-V's "short interest". This figure is 12.4% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting CureVac N-V stocks can be evaluated.
CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V stocks currently shorted divided by the average quantity of CureVac N-V stocks traded daily (recently around 728954.6474359). CureVac N-V's SIR currently stands at 6.24. In other words for every 100,000 CureVac N-V stocks traded daily on the market, roughly 6240 stocks are currently held short.
However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V stocks, or, against the total number of tradable CureVac N-V stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 CureVac N-V stocks in existence, roughly 20 stocks are currently held short) or 0.0565% of the tradable stocks (for every 100,000 tradable CureVac N-V stocks, roughly 57 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against CureVac N-V.
Find out more about how you can short CureVac N-V stock.
We're not expecting CureVac N-V to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Everything we know about the ACV Auctions Inc IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.